AusBiotech announces formation of the AusMedtech Health Economics Expert Panel
09 November, 2011 by AusBiotechA new health economics panel has been launched to advise on key issues affecting medical devices companies regarding the assessment and reimbursement of medical devices diagnostics in Australia.
QRxPharma gets target date for MoxDuo IR FDA approval
08 November, 2011 by Staff WritersPending approval by the FDA, QRxPharma's (ASX:QRX) MoxDuo IR could be given the go ahead for sale by June 25 2012.
AusBiotech and PwC webcast gives update on the state of the nation's biotechnology sector
08 November, 2011 by AusBiotechThe latest in the series of webcasts that discuss the latest happenings in the sector with AusBiotech and the results of PricewaterhouseCoopers' (PwC) BioForum quarterly report is out now.
Immuron submits IND for liver disease drug
08 November, 2011 by Staff WritersImmuron (ASX:IMC) to commence phase IIb clinical trial for drug to treat fatty liver disease, including Nonalcoholic steatohepatitis (NASH).
Alchemia to spin off oncology business
07 November, 2011 by Tim DeanAlchemia (ASX:ACL) intends to create new wholly-owned oncology business to develop chemotherapy drug delivery technology, HyACT.
Circadian to start phase I trials for cancer drug after receiving IND approval
04 November, 2011 by Staff WritersCircadian (ASX:CIR) to initiate phase I trials after receiving investigational new drug status from the Food and Drug Administration for VGX-100 anti-cancer drug.
Clinuvel’s Scenesse sees positive trial results
04 November, 2011 by Staff WritersA phase II study of Clinuvel’s (ASX:CUV) photoprotective Scenesse shows it is effective and safe in treating the rare disorder, erythropoietic protoporphyria (EPP).
Joint venture saves Living Cell Technologies from closure
02 November, 2011 by Tim DeanA 50/50 joint venture with Japanese Otsuka Pharmaceutical Factory has injected $25 million into the company which was running perilously short on cash.
Market Watch: Mesoblast shares down 14%
31 October, 2011 by Tim DeanMesoblast (ASX:MSB) has seen its share price drop 14% in the last two days after being downgraded to "underperform" by Macquarie Research.
Biotechs receive investment interest following AusBiotech 2011
28 October, 2011 by Staff WritersForeign investors have expressed interest in a number of Australian biotechnology companies following the AusBiotech 2011 conference last week.
ResMed profits dented by high Australian dollar
25 October, 2011 by Staff WritersResMed has posted a record quarterly revenue of $314.8 million, but an 11% decrease in net income due to the high Australian dollar.
Pharmaxis shares soar as Europe set to approve Bronchitol
24 October, 2011 by Staff WritersCystic fibrosis treatment, Bronchitol, has been recommended for approval in Europe, seeing Pharmaxis (ASX:PXS) shares jump by nearly 60 per cent.
Phosphagenics raises $24.1m to fund oxycodone patch trial
21 October, 2011 by Staff WritersAdditional $3 million to be raised in share purchase plan to fund clinical trials in anticipation of FDA registration in 2013.
Australian biotechs showcased at investment summit
19 October, 2011 by Staff WritersAustralia's top biotech companies are showing their wares to investors from around the world at the AusBiotech Australasian Life Sciences Investment Summit.
AusBiotech 2011: Healing touch
17 October, 2011 by Tim DeanAustralian labs are conducting pioneering research into tissue regeneration, such as the new treatment for severe burns, NovoSkin.
